|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,264,446
Summary
U.S. Patent 5,264,446 (hereafter "the '446 patent") was granted on November 23, 1993, and covers pharmaceutical compositions involving the bisphosphonate class of compounds, specifically targeting treatment of bone diseases such as osteoporosis. This patent plays a significant role in establishing foundational claims around bisphosphonate derivatives, their methods of use, and formulations, influencing subsequent innovation and patent filings in the field of bone therapeutics. This analysis examines the scope of the patent claims, their legal boundaries, and the broader patent landscape that emerged around this patent over time.
Scope and Claims of U.S. Patent 5,264,446
1. Primary Claims Coverage
The patent primarily claims:
- Chemical compounds: Specific bisphosphonate derivatives with certain substituents.
- Methods of use: Therapeutic applications, especially inhibiting bone resorption or treating osteoporosis.
- Pharmaceutical formulations: Methods for preparing compositions containing the claimed compounds.
2. Claim Structure and Independent Claims
| Claim Type |
Claim Number |
Content Summary |
Key Elements |
| Independent Claims |
1, 2, 7 |
Cover the chemical structures, especially compounds with specific R groups attached to the bisphosphonate scaffold |
Core chemical framework, substituents R1, R2, R3, etc. |
| Dependent Claims |
3-6, 8-11 |
Narrower claims detail specific substituents, stereochemistry, salts, forms |
Specific chemical variations and embodiments |
Example of Claim 1 (paraphrased):
“An organic bisphosphonate compound of the formula:
[ \mathrm{R^1R^2C(OH)CH_3N(P(OH)_2)_2} ]
wherein R1 and R2 are selected from a specific group of substituents.”
3. Scope Analysis
The claims focus on bisphosphonate derivatives characterized by specific substituents on the carbon backbone, notably those with enhanced antiresorptive potency owing to modifications at particular sites. The scope covers:
- Chemical structure limitations: Ensuring the compounds fall within the claimed formulas; other structural variations are outside scope.
- Uses: The exclusive application in inhibiting osteoclast activity, thus relevant for osteoporosis, Paget's disease, and metastatic bone cancer.
4. Claim Language and Legal Boundaries
- Structural specificity limits the scope to particular compounds; broad claims could encompass numerous analogs.
- Use claims are confined to specific methods, potentially subject to research exemption policies.
- Formulation claims suggest specific pharmaceutical preparations, broadening the scope to include various delivery forms.
Patent Landscape Overview
1. Chronology and Related Patents
| Year |
Key Developments |
Notable Patents |
Comments |
| 1987 |
Priority applications filed (e.g., EP 0 217 644 A, US 4,753,939) |
Early bisphosphonate patents |
Focused on drug chemistry & synthesis |
| 1993 |
'446 patent issued |
US 5,264,446 |
First substantial patent on specific bisphosphonate compounds |
| 1994-2000 |
Expansion of patent family |
Supplementary patents on formulations, methods |
Increased patent staking for leading compounds like alendronate, risedronate |
| 2000 onward |
Patent term expiration approaches |
Generic entries emerge |
Generics begin to challenge patent scope in courts |
2. Key Patent Families and Influences
| Patent Family |
Main Claims |
Relation to '446 |
Status |
| Johnson & Johnson / Merck |
Compound claims on alendronate |
Based on similar scaffold but distinct compounds |
Expired or under litigation |
| Novartis / Roche |
Risedronate-related patents |
Overlapping but distinct chemical structures |
Several extensions and disputes |
| Amgen |
Zoledronic acid formulations |
Different compound class but within bisphosphonate class |
Patent term extended via terminal disclaimers |
Note: The '446 patent forms a part of a broad patent landscape where companies secured rights on different bisphosphonates, their formulations, and use methods.
3. Legal Status and Expirations
- The '446 patent expired on November 23, 2011 (20-year term from filing).
- Post-expiration, the landscape shifted toward generic manufacturing of bisphosphonates.
- Patent litigations and disputes centered on similar compounds' patentability, inventive step, and scope.
4. Regulatory and Patent Policy Context
The patent landscape was influenced by:
- FDA approvals: For drugs like alendronate (Fosamax), approved in 1995, which builds on compounds within the '446 patent's scope.
- Patent term extensions: Applied in some jurisdictions, extending exclusivity.
- Patent cliff: Post-expiration, generic versions flooded the market → significant impact on market dynamics.
Comparison with Subsequent Patents
| Aspect |
'446 Patent |
Later Patents |
Differences |
Relevance |
| Scope |
Core bisphosphonate derivatives |
Specific derivatives, formulations, methods |
Broader in some cases, narrower in others |
Foundation for later innovations |
| Focus |
Chemical structure |
Use cases, delivery mechanisms |
Use claims more detailed |
Extending patent coverage beyond initial compounds |
| Legal Status |
Expired 2011 |
Many have expired or faced challenges |
Generic manufacturing now dominant |
Significant for patent clearance |
FAQs
What is the primary chemical scope of U.S. Patent 5,264,446?
The patent covers specific bisphosphonate compounds with defined substituents attached to a core phosphorus-containing scaffold, mainly targeting antiresorptive properties for bone diseases.
How broad are the claims in this patent?
The independent claims define a chemical scaffold with particular substituents, making the scope relatively narrow to specific derivatives. Use and formulation claims supplement this, but the core chemical claims are structurally limited.
What role does this patent play in the broader bisphosphonate patent landscape?
It is foundational, underpinning subsequent patents on major drugs like alendronate and risedronate. Many later patents build upon or are inspired by the chemical structures disclosed in the '446 patent.
Has the '446 patent been litigated or challenged?
Given its expiration in 2011, it's no longer enforceable. While earlier disputes potentially involved related compounds, currently, the landscape involves patents on newer bisphosphonates or methods.
How has the patent expiration affected market dynamics?
Post-expiration, generic manufacturers rapidly introduced biosimilar versions, significantly reducing drug prices and expanding access to bisphosphonate therapies globally.
Key Takeaways
- The '446 patent's claims target specific bisphosphonate derivatives with well-defined substituents, contributing to its narrow but solid scope.
- It forms a core patent in the bisphosphonate class, influencing subsequent drug development and patent filings.
- Patent landscape analyses reveal a strategic expansion into formulations, methods, and derivatives, affecting market exclusivity.
- With its expiration in 2011, the landscape shifted toward generics, impacting pricing, availability, and new research directions.
- Understanding the claims' precise language and scope is crucial for assessing freedom-to-operate and designing around strategies in this area.
References
- U.S. Patent 5,264,446. Issued November 23, 1993.
- FDA Approval of Fosamax. U.S. Food and Drug Administration, 1995.
- Patent Families and Litigation Data. PatentScope, WIPO, 2023.
- Regulatory and Patent Policy Reports. U.S. Patent and Trademark Office, 2021.
- Analysis of Bisphosphonate Patent Landscape. Johnson & Johnson, Merck, Novartis filings.
More… ↓
⤷ Start Trial
|
